Objective: We assessed clinical effectiveness, longevity of treatment effects, and patient satisfaction with incobotulinumtoxinA for glabellar frown lines (GFL) treatment in Asian patients.
J Clin Aesthet Dermatol. 2018;11(12):30–39 by Joan Vandeputte, MD, FCCP (Belgium) Dr. Vandeputte is a Fellow of the European Board of Plastic, Reconstructive, and Aesthetic Surgery and a plastic surgeon in private practice and at Oudenaarde General Hospital in Belgium. FUNDING: Merz Pharmaceuticals GmbH provided a restricted grant to support data collection and analysis. DISCLOSURES:
by Joseph F. Fowler, MD; James Q. Del Rosso, DO; Refika I. Pakunlu, PhD; and Srinivas Sidgiddi, MD Dr. Fowler is Co-Founder of Dermatology Specialists Research in Louisville, Kentucky, and Clinical Professor of Dermatology, University of Louisville School of Medicine, Louisville, Kentucky. Dr. Del Rosso is Research Director at JDR Dermatology Research in Las Vegas,
by Brian Berman, MD, PhD; Stephen Tyring, MD, PhD; Walter K. Nahm, MD, PhD; Marie Louise Østerdal, MSc; Astrid H. Petersen, PhD; and Daniel M. Siegel, MD Dr. Berman is Co-Director at Center for Clinical and Cosmetic Research in Aventura, Florida. Dr. Tyring is Medical Director at the Center for Clinical Studies at University of